Invesco Nasdaq Biotechnology ETF

Gilead Sciences COO Selling Company's Common Stock

Insiders at United Therapeutics Sell $1.74 Million in Shares

United Therapeutics CEO Sells Company Shares

United Therapeutics Director Disposes of Common Stock

LEQEMBI Added to China's Commercial Insurance List of Innovative Drugs

Jefferies Analyst Maintains Buy Rating for Argenx Se with Price Target at $950

Cantor Fitzgerald Maintains Buy Rating on Insmed

Aliraum Pharmaceuticals' AMVUTTRA® Approved by Health Canada

Stifel Nicolaus analyst maintains buy rating on Biogen

AstraZeneca's Saphnelo approved for treating systemic lupus erythematosus

AstraZeneca and Daiichi Sankyo Receive FDA Approval for ENHERTU® in Combination with Pertuzumab for First-Line Treatment of HER2-Positive Breast Cancer

Leerink Partners Cuts AliraM Pharmaceuticals Target Price to $351

AstraZeneca's Enhertu Approved for First-Line HER2-Positive Metastatic Breast Cancer Treatment

Goldman Sachs Raises Insmed's Target Price to $258 and Maintains Buy Rating

Gilead Sciences' HIV Treatment Regimen BIC/LEN Phase 3 Study Shows Positive Results

Wall Street Zen Upgrades Amgen's Stock Rating to 'Strong Buy'

arGEN-X SE Halts Phase III Clinical Trial of Efgartigimod for Thyroid Eye Disease

AstraZeneca Completes tozorakimab Delivery Method Clinical Study

Morgan Stanley Maintains Hold Rating on Alnylam Pharmaceuticals

Stance Capital LLC Increased Holdings in Gilead Sciences in Q2

Vision Marine Tech

AMC Robotics

B Riley Financial

Cementos Pacasmayo Saa 

Everbright Digital

Adagio Medical

Emerald

ChowChow Cloud

AdvisorShares MSOS 2x Daily ETF

Biodexa Pharmaceuticals

GILD

CFO Andrew D. Dickinson of Gilead Sciences Inc. sold 3,000 shares worth $366,000 on December 15, 2025, under a prearranged trading plan (10b5-1). His ending holdings are 153,503 shares. The transaction was disclosed in a Form 4 filed with the SEC.

Reuters

Gilead Sciences

CFO Dickinson Sells 3,000 ($366K) Of Gilead Sciences Inc [GILD]

Andrew D. Dickinson, CFO of Gilead Sciences Inc., reported the disposal of common shares of the company. The filing is available via EDGAR, the SEC's system. This news is AI-generated by Public Technologies and is not financial advice.

Gilead CFO Andrew D. Dickinson Reports Disposal of Common Shares

Johanna Mercier, Chief Commercial Officer of Gilead Sciences Inc., has sold common shares of the company. This information was disclosed through a filing on the U.S. SEC's EDGAR system. The news was generated by Public Technologies using AI and is for informational purposes only.

Gilead Sciences Chief Commercial Officer Johanna Mercier Sells Common Shares

UTHR

United Therapeutics Insider Sold Shares Worth $3,952,689, According to a Recent SEC Filing

marketscreener

United Therap

United Therapeutics Insider Sold Shares Worth $3,952,689, According to a Recent SEC Filing

United Therapeutics Insider Sold Shares Worth $1,742,193, According to a Recent SEC Filing

United Therapeutics Insider Sold Shares Worth $1,742,193, According to a Recent SEC Filing

Martine A. Rothblatt, CEO of United Therapeutics, reported selling common shares of the company. This announcement was made via EDGAR by the U.S. SEC. The information is for informational purposes and not financial advice.

United Therapeutics CEO Martine Rothblatt Reports Sale of Common Shares

BIIB

Biogen Inc.'s stock fell 2.41% to $171.50 on Tuesday, underperforming compared to competitors like Johnson & Johnson, Pfizer, and AbbVie. The stock's decline ended a two-day winning streak and was part of a broader market downturn, with the S&P 500 and Dow Jones also falling. Biogen's trading volume exceeded its 50-day average, and the stock remains 7.38% below its 52-week high.

Dow Jones

Biogen

Biogen Inc. Stock Underperforms Tuesday When Compared To Competitors

United Therapeutics Insider Sold Shares Worth $11,166,722, According to a Recent SEC Filing

United Therapeutics Insider Sold Shares Worth $11,166,722, According to a Recent SEC Filing

Christopher Patusky, Director of United Therapeutics Corporation, reported the disposal of common shares. This announcement was made via EDGAR by the U.S. Securities and Exchange Commission on December 16, 2025. The full filing is accessible online.

United Therapeutics Director Christopher Patusky Reports Disposal of Common Shares

AstraZeneca received FDA approval for Enhertu, in combination with pertuzumab, for first-line treatment of HER2-positive breast cancer, reducing disease progression risk by 44%. Additionally, the EU approved Saphnelo for lupus self-injection. AstraZeneca owes Daiichi Sankyo $150 million for the Enhertu approval. AstraZeneca will pay royalties to Bristol-Myers for Saphnelo sales. AstraZeneca shares fell 1.03% to $90.62.

benzinga_article

Astrazeneca

AstraZeneca Gets FDA Nod For Breast Cancer Drug, EU Clearance For Lupus Pen

Eisai Co., Ltd. and Biogen Inc. announced that their drug LEQEMBI (lecanemab) for early Alzheimer's treatment has been included in China's Commercial Insurance Innovative Drug List by the NHSA. This inclusion aims to expand access to innovative medicines in China, addressing significant unmet needs. The list will take effect on January 1, 2026, facilitating discussions between insurance and pharmaceutical companies for coverage details.

Japan Corporate News

"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List

INSM

Cantor Fitzgerald's Olivia Brayer maintains a Buy rating for Insmed (INSM) with a $230 price target. Brayer, a 3-star analyst, has a 7.9% average return and a 46.03% success rate. Insmed also received a Buy rating from Goldman Sachs, while TR reiterated a Hold rating. Brayer focuses on healthcare stocks like CytomX Therapeutics and BioMarin Pharmaceutical.

Tip Ranks

Insmed

Cantor Fitzgerald Sticks to Their Buy Rating for Insmed (INSM)

ALNY

Alnylam Pharmaceuticals Inc :ALNYLAM ANNOUNCES HEALTH CANADA APPROVAL OF AMVUTTRA® (VUTRISIRAN), THE FIRST AND ONLY RNAI THERAPEUTIC FOR THE TREATMENT OF CARDIOMYOPATHY IN ADULT PATIENTS WITH ATTR AMYLOIDOSIS

Alnylam Pharma

Alnylam Announces Health Canada Approval Of Amvuttra®

Alnylam (NASDAQ:ALNY) has corrected by 13% recently, entering Phase 11 of its Adhishthana cycle. The stock formed a peak near 495.55 and is now in a corrective phase, declining over 20%. Investors are advised against aggressive buying and should consider hedging, as the stock may revisit Phase 9 levels before the descent phase concludes.

Is Alnylam Entering A Corrective Phase After A Strong Run?